Open Access
The effect of pharmacological treatment on ADMA in patients with heart failure
Graziano Riccioni1,Lorenza Speranza1,Luca Scotti1,Valentina Bucciarelli1,Emanuela Di Ilio1,Nicolantonio D'Orazio1,Mirko Pesce1,Antonio Aceto1,Valeria Sorrenti1,Alessandro Frigiola1,Tonino Bucciarelli1
Cardiology Unit, San Camillo de Lellis Hospital, Manfredonia, Foggia, Italy.
DOI: 10.2741/E334 Volume 3 Issue 4, pp.1310-1314
Published: 01 June 2011
(This article belongs to the Special Issue Biochemical markers in biological fluids)

Asymmetric dimethylarginine (ADMA) plays a crucial role in the arginine-nitric oxide (NO) pathway. NO plays an important role in controlling vascular tone and regulates the contractile properties of cardiac myocytes. The purpose of this study was to investigate the effect of pharmacological treatment on asymmetrical dimethylarginine (ADMA) plasma levels in patients with acute congestive heart failure (HF). Patients with symptomatic acute congestive HF (NYHA Class III-IV) and impaired left ventricular (LV) function (ejection fraction less than 40 percent) were included in the study. ADMA and SDMA concentrations were assessed before and after pharmacological treatment in 18 critically ill patients on the intensive care unit by high performance liquid chromatography. All patients received a complete pharmacological treatment (diuretics, digoxin, ACE-inhibitors or angiotensin receptor blockers, and nitroglicerin) for the treatment of acute congestive HF. ADMA plasma levels of critically ill patients were significantly higher after pharmacological treatment respect baseline values (pre-treatment). In critically ill patients with acute congestive HF acute renal impairment function and the modulation of NOS determine plasma ADMA/SDMA levels after therapy.

Share and Cite
Graziano Riccioni, Lorenza Speranza, Luca Scotti, Valentina Bucciarelli, Emanuela Di Ilio, Nicolantonio D'Orazio, Mirko Pesce, Antonio Aceto, Valeria Sorrenti, Alessandro Frigiola, Tonino Bucciarelli. The effect of pharmacological treatment on ADMA in patients with heart failure. Frontiers in Bioscience-Elite. 2011. 3(4); 1310-1314.